spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  UCB  

 HSMN NewsFeed - 16 Jan 2025
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX(R) (bimekizumab-bkzx)
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 5 Dec 2024
Sapience Therapeutics Strengthens Board of Directors and Management Team with Esteemed Business Development Executives
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Sep 2024
UCB Announces U.S. FDA Approvals for BIMZELX(R) (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Dec 2021
UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Apr 2021
Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss
Regenerative Medicine Venture Capital
 HSMN NewsFeed - 26 Jan 2021
Connect Biopharma Strengthens Leadership Team with Key Hire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Aug 2020
StrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jul 2020
UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 24 Jul 2020
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 5 Jun 2020
UCB Acquires Engage Therapeutics: Staccato(R) Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
Devices Drug Delivery Neurology Mergers & Acquisitions
 HSMN NewsFeed - 5 May 2020
Ichnos Sciences Appoints David Lubner To Board Of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2019
European Commission Approves EVENITY(R) (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Oct 2019
EVENITY(R) (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 May 2019
UCB announces NAYZILAM(R) (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 20 May 2019
Rinri Therapeutics Secures £1.4 Million Seed Funding to Advance Its Novel Regenerative Cell Therapy to Treat Sensorineural Hearing Loss
Regenerative Medicine Venture Capital Personnel
 HSMN NewsFeed - 2 Apr 2019
Provention Bio Announces Key Additions to its Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2019
EVENITY(TM) (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Jan 2019
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2018
Ceribell Announces Completion Of $35 Million Series B Financing
Devices Monitoring Neurology Venture Capital
 HSMN NewsFeed - 13 Jul 2018
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jun 2018
StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 20 Apr 2018
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 23 Oct 2017
EMD Serono Appoints Robert Truckenmiller to Senior Vice President of Market Access & Customer Solutions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2017
New indication for BRIVIACT(R) (brivaracetam): UCB's newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 Jul 2017
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 May 2017
Homology Medicines Strengthens Manufacturing and Product Development Expertise with Appointment of Tim Kelly as Senior Vice President, Technical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2017
Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY(TM) (Romosozumab) In Postmenopausal Women With Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 26 Apr 2017
John Tucker appointed as Chief Executive Officer of scPharmaceuticals
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 3 Oct 2016
Launch of Carrick Therapeutics Signals New Approach to Cancer Therapies
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Sep 2016
aTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J. King, PhD, as Senior Vice President, Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jul 2016
Amgen and UCB Submit Biologics License Application for Romosozumab to the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 May 2016
Neos Therapeutics Announces U.S. Launch of Adzenys XR-ODT(TM) (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients Six Years and Older
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 24 Mar 2016
Ajanta Pharma Announces the Launch of Levetiracetam Tablets
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 21 Mar 2016
Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 22 Feb 2016
Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 28 Jan 2016
Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT(TM) (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients 6 Years and Older
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 27 Nov 2015
Lannett Completes Major Acquisition Of Kremers Urban Pharmaceuticals For $1.23 Billion
Biopharmaceuticals Generic Mergers & Acquisitions
 HSMN NewsFeed - 19 Aug 2015
Immunomedics Appoints Arthur S. Kirsch as Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Jun 2015
Opexa Hires Experienced Pharmaceutical Executive as Vice President of Business Development
Biopharmaceuticals Personalized Medicine Personnel
 HSMN NewsFeed - 3 Oct 2014
Allied-Bristol Life Sciences Appoints Former Bristol-Myers Vice President Satish Jindal to Lead the Discovery of Drug Candidates From Leading Academic Institutions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Aug 2014
Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
Biopharmaceuticals Dermatology Venture Capital Personnel
 HSMN NewsFeed - 6 Aug 2014
Nodality Expands Senior Leadership Team, Appoints Kathleen LaPorte as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Mar 2014
Mike Sullivan named President of Avion Pharmaceuticals, LLC
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 26 Feb 2014
Nodality, Inc. Appoints Ralph Snyderman, M.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2014
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Jan 2014
Osiris Therapeutics Board Confirms Lode Debrabandere, PhD, MBA, as President and Chief Executive Officer
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 3 Jan 2014
Aeterna Zentaris Appoints Dr. Richard Sachse as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Sep 2013
Alkermes Expands Senior Management Team
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Jul 2013
BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 17 May 2013
New Study Shows Effect of Neupro(R) (Rotigotine Transdermal System) on Cardiovascular Measures in Patients with Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 30 Oct 2012
BioNTech AG Appoints Sean Marett as COO (Chief Operating Officer)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Oct 2012
Osiris Therapeutics Names Lode Debrabandere Chief Operating Officer
Regenerative Medicine Wound Care Personnel
 HSMN NewsFeed - 24 Sep 2012
Nodality, Inc. Appoints Laura Brege as Chief Executive Officer
Personalized Medicine Personnel
 HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Diagnostics Personalized Medicine Gastroenterology
 HSMN NewsFeed - 16 Jul 2012
UCB Launches Neupro(R) in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome
Biopharmaceuticals Neurology Drug Delivery
 HSMN NewsFeed - 23 May 2012
APP Pharmaceuticals Acquires Three Products from Nexus
Biopharmaceuticals Generics Acquisitions
 HSMN NewsFeed - 10 May 2012
Incline Therapeutics Announces Appointment of John Tucker as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2012
Neupro(R) Approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 Feb 2011
Alios BioPharma Names Carol L. Brosgart, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Oct 2010
Synosia Therapeutics Raises $30M in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 13 Sep 2010
AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Aug 2010
Cornerstone Therapeutics Announces Development of Generic for Tussionex(R)
Biopharmaceuticals Generics
 HSMN NewsFeed - 29 Jul 2010
Actient Pharmaceuticals, LLC Closes Transaction to License and Acquire Specialty Pharmaceutical Products from UCB
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 28 Jul 2010
Study Showed the Clinically Significant Therapeutic Benefit of Neupro(R) (rotigotine transdermal system) in the Treatment of Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 23 Jun 2010
Stryker Announces Election of New Director
Devices Orthopaedic Personnel
 HSMN NewsFeed - 18 Jun 2010
Neupro(R) (rotigotine) significantly improved wellbeing and daily activities impaired due to limb pain associated with Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 17 Jun 2010
Neupro(R) (rotigotine transdermal system) Showed Significant Benefit on Early Morning Motor Control, Sleep and Nocturnal Symptoms in Patients With Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Jun 2010
New Data Presented from EMBLEM Study for Pipeline Drug Epratuzumab for Patients Suffering from Moderate to Severe Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 3 May 2010
VIVUS Appoints Michael Miller to Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2010
UCB Receives Complete Response Letter from U.S. FDA Regarding Neupro(R) (Rotigotine)
Biopharmaceuticals Drug Delivery Neurology FDA
 HSMN NewsFeed - 13 Apr 2010
New Data Show Sustained 5-Year Benefit of Neupro(R) (Rotigotine Transdermal System) for Symptoms of Restless Legs Syndrome
Biopharmaceuticals Neurology Drug Delivery
 HSMN NewsFeed - 10 Nov 2009
Ismail Kola joins UCB as Executive Vice President, UCB & President of UCB New Medicines(TM)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 24 Aug 2009
FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Jun 2009
Clinical Data Presented at International Congress Showed Treatment With Neupro(R) (rotigotine) Significantly Improved Early Morning akinesia and was Generally Well Tolerated Over Four Years
Biopharmaceuticals Neurology
 HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 29 May 2009
UCB receives CHMP positive opinion on bringing Neupro(R) back to all patients in Europe
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 13 May 2009
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Apr 2009
New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Feb 2009
UCB to divest Equasym(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 20 Feb 2009
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 Feb 2009
Dr. Reddy's Announces Five ANDA Approvals and Generic Product Launches in the US Market
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 16 Jan 2009
Lupin is Granted USFDA Approval for Levetiracetam Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 9 Jan 2009
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Dec 2008
Cambridge Laboratories Announces Approval of Tetrabenazine in Spain
Biopharmaceuticals Reimbursement Distribution
 HSMN NewsFeed - 4 Nov 2008
Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 27 Oct 2008
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Biopharmaceuticals
 HSMN NewsFeed - 7 Oct 2008
MiddleBrook Pharmaceuticals Announces Changes to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 25 Sep 2008
UCB Withdraws EU Marketing Authorisation Application for Lacosamide in Diabetic Neuropathic Pain
Biopharmaceuticals
 HSMN NewsFeed - 16 Sep 2008
Changes in UCB's Executive Committee
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2008
Keppra XR(TM) Approved in the U.S.
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 8 Sep 2008
Perrigo Acquires Exclusive Sales and Distribution Rights to Allergy Drug Levocetirizine from Synthon
Biopharmaceuticals Generics Distribution
 HSMN NewsFeed - 14 Jul 2008
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 10 Jun 2008
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2008
US FDA grants pediatric exclusivity for UCB's Keppra(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 8 May 2008
New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 25 Apr 2008
Neupro(R) recommended for approval in Europe for Restless Legs Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Apr 2008
FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 22 Apr 2008
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 20 Mar 2008
CHMP Upholds Negative Opinion for the EU Application for Cimzia(R) in the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 20 Mar 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2008
UCB advises US-physicians to down-titrate patients on Neupro(R) in view of out-of-stock situation in the US
Biopharmaceuticals Neurology Product Recall
 HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Mar 2008
UCB: Early Data on Cimzia(R) from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 3 Mar 2008
Changes in UCB's Executive Committee
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Feb 2008
FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Feb 2008
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jan 2008
Teva Specialty Pharmaceuticals and UCB Announce U.S. Respiratory Collaboration Agreement
Biopharmaceuticals
 HSMN NewsFeed - 13 Dec 2007
Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 13 Dec 2007
Neupro(R) Filed with the FDA for the Treatment of Restless Legs Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Dec 2007
New Phase III Trial Shows Positive Outcome of lacosamide in Patients with Diabetic Neuropathic Pain
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2007
Epratuzmab Plus Rituximab Produce Durable Complete Responses in Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Dec 2007
Neupro(R) Filed in Europe for the Treatment of Restless Legs Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Dec 2007
UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Dec 2007
UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Nov 2007
UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain
Biopharmaceuticals
 HSMN NewsFeed - 29 Nov 2007
UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Nov 2007
UCB to Appeal European Negative Opinion on CIMZIA(R) for the Treatment of Patients with Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 26 Oct 2007
UCB Announces Initiation of Phase III Clinical Program for RikeltaTM (brivaracetam) as Adjunctive Treatment in Partial-Onset Epilepsy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Oct 2007
Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
Biopharmaceuticals Neurology Drug Delivery
 HSMN NewsFeed - 8 Oct 2007
Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease
Biopharmaceuticals Neurology Drug Delivery
 HSMN NewsFeed - 20 Aug 2007
Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 17 Aug 2007
UCB Announces Submission of Lacosamide Marketing Application for Diabetic Neuropathic Pain
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Aug 2007
Immunomedics Appoints Edward T. Wolynic to Board Of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jul 2007
Neuren to Obtain Late Stage Compound Through Hamilton Pharmaceuticals Acquisition
Biopharmaceuticals Acquisitions Neurology
 HSMN NewsFeed - 18 Jul 2007
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 16 Jul 2007
UCB Announces the U.S. Launch of Neupro(R) (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Jul 2007
SCHWARZ PHARMA and UCB, Inc. Announce U.S. Launch of Neupro(R) (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Jul 2007
StemCyte Appoints Robert Dickey IV as Senior Vice President and Chief Financial Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 10 Jul 2007
ViroPharma Announces Key Additions to European Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jun 2007
UCB and Biogen Idec's Oral VLA-4 Antagonist Enters Phase II Development for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 13 Jun 2007
ARIAD Announces Appointment of Senior Oncology Executive to Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2007
Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2007
FDA Approves XYZAL(R) (Levocetirizine Dihydrochloride) Tablets for the Relief of Seasonal and Year Round Allergies, and Chronic Hives
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2007
UCB Presents Long-Term CIMZIA(TM) Data in Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 20 Apr 2007
UCB Announces Positive Top-Line Phase III Results for Keppra(R) as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Mar 2007
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and Rheumatoid Arthritis in the US
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 20 Mar 2007
Keppra(R) Approved for US Epilepsy Patients with One of the Most Debilitating Seizure Types
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 14 Mar 2007
Anthony Tebbutt Joins Alexza Pharmaceuticals as Senior Vice President, Corporate Strategy & Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Mar 2007
New European Approval for Xyrem(R) Provides Significant Advance in the Treatment of Narcolepsy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Feb 2007
Significant Phase III Results with CIMZIA(TM) in Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Feb 2007
ImClone Systems Opts-out of Development Agreement with UCB to Focus Resources on Proprietary, Anti-VEGFr-2 Antibody IMC-1121B
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2007
More European Patients With Epilepsy to Benefit From Keppra(R)
Biopharmaceuticals Regulatory Neurology
 HSMN NewsFeed - 22 Dec 2006
UCB Announces Positive Results From Two New Phase III Studies in Rheumatoid Arthritis and Provides Update on the Status of US Approval for CIMZIATM in the Treatment of Crohn's Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Dec 2006
Intranasal Therapeutics, Inc. Adds Key Executives to Management Team
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 4 Dec 2006
Study Showed Epratuzumab in Combination with Rituximab and Chemotherapy is Safe, Tolerable, and Active in Aggressive Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Dec 2006
Amgen Names Yuji Orihara President, Amgen KK
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2006
FDA Allows Resumption of Lupus Trials with Epratuzumab
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
Epratuzumab and Rituximab Have Different Modes of Action
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2006
New Data Show CIMZIA(TM) (certolizumab pegol) May Improve Productivity in Work and with Daily Activities for People with Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Analysis Shows CIMZIA(TM) (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Efficacy Data Show CIMZIA(TM) (Certolizumab Pegol) Maintained Response and Remission in Crohn's Patients Previously Treated With Infliximab
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 3 Oct 2006
UCB and Jazz Pharmaceuticals Announce Expansion of Xyrem(R) License Agreement to Include Fibromyalgia Syndrome
Biopharmaceuticals Licensing
 HSMN NewsFeed - 25 Sep 2006
sanofi-aventis and UCB Sign a Co-Promotion Agreement for Xyzal(R) in the United States
Biopharmaceuticals
 HSMN NewsFeed - 25 Sep 2006
UCB and sanofi-aventis sign a co-promotion agreement for Xyzal(R) in the United States
Biopharmaceuticals
 HSMN NewsFeed - 19 Sep 2006
UCB Appoints Fabrice Egros, Ph.D., MBA, President of U.S. Subsidiary
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jul 2006
AtheroGenics Announces Promotion of Joseph M. Gaynor, Jr. to Senior Vice President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jul 2006
A Key Regulatory Milestone for Keppra
Biopharmaceuticals Regulatory Neurology
 HSMN NewsFeed - 27 Jun 2006
Auriga Laboratories Promotes Senior Vice President of Sales and Marketing Andrew Shales to Position of Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 May 2006
UCB Sells to Adams Respiratory Therapeutics OTC Delsym(R) 12-Hour Cough Suppressant Liquids
Biopharmaceuticals Licensing
 HSMN NewsFeed - 24 May 2006
UCB Completes Mutual Recognition Procedure for Equasym(TM) XL
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 May 2006
New CIMZIA (TM) Data from PRECiSE Program Reinforce Robust Efficacy in Once-Monthly Treatment of Crohn's Disease and Consistent Tolerability Profile
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 15 May 2006
European Commission Approves Keppra(R) for Use as Adjunctive Therapy in the Treatment of Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 10 May 2006
UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab
Biopharmaceuticals Licensing
 HSMN NewsFeed - 10 May 2006
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 51

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 51 additional stories matching:
UCB
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.